Jinan Hongyuan Chemical Co.,Ltd

Jinan Hongyuan Chemical Co.,Ltd

info@hychem-china.com

86-13954187575

Jinan Hongyuan Chemical Co.,Ltd
Casa> Blog
July 19, 2021
Frontier | Research progress of kinase inhibitors in the treatment of coronavirus infections

As of now, the cumulative number of COVID-19 infections worldwide has exceeded 187 million, and about 4 million have died (Figure 1). Although relevant vaccines hav

July 17, 2021
Hengrui's Class 1 new drug SHR3680 in the treatment of stage III prostate cancer reaches the primary research endpoint

Recently, Hengrui Medicine's Class 1 new drug SHR3680 combined with androgen deprivation therapy (ADT) compared to standard the

July 16, 2021
15 blockbuster drugs expire patents! BMS accounted for 3 models, Merck & Co., Ltd. 2 models, AbbVie, Novartis, Pfizer...

In 10 years, the situation is changing, and the pharmaceutical field will also undergo significant changes. In particular, a batch of super "blockbusters" will fall

July 13, 2021
Review of the first half of 2021: Hotview Biotech's growth rate is the first, and medical equipment welcomes IPO financing

In the first half of 2021, due to the impact of the new crown epidemic in some regions, pharmaceutical companies such as medica

July 12, 2021
[Yao Ka Jun] 27 new drugs have been approved for clinical use, and “first-in-class” new drugs are still mainly introduced, BeiGene, Kelun, Zai Lab...

Yaozhi data shows that in this period (July 2 to July 9), 27 new drugs were approved clinically (40 acceptance numbers); another 39 varieties (60 acceptance numbers

July 10, 2021
Cinda Biotech's first small molecule anti-cancer drug, pemigatinib, has been declared for the market !

July 9, 2021, San Francisco, USA and Suzhou, China-Cinda Biopharmaceuticals (Hong Kong Stock Exchange stock code: 01801), a company dedicated

July 09, 2021
Dry goods! Analysis report of CDE drug review in the first half of 2021

一. In the first half of 2021, the overall situation of drug registration applications

July 08, 2021
The tragedy of Chinese innovative drugs? First in class has not yet sprouted, but "pseudo-innovation" has become a target of severe crackdown...

On July 2, the Drug Evaluation Center of the National Medical Products Administration issued a notice for publicly soliciting o

July 07, 2021
White horse stumbles! The listing of 8 innovative drugs still plummeted, what happened to Hengrui?

On July 2, 2021, the Center for Drug Evaluation (CDE) of the National Medical Products Administration issued the "Guiding Princ

July 06, 2021
Looking at the development of Chinese medicine from the reform of the patent system

Patent right is an intangible property right, and the essence of the patent system is to protect innovation. With the evolution of the international and domestic ec

July 05, 2021
The first imitation in China! United Laboratories' "Somaglutide" clinical trial application accepted

On June 29, 2021, Zhuhai United Laboratories Co., Ltd. announced that it had received the Notice of Acceptance of Clinical Registration Application for Semaglutide Injection (Semaglutide Injection) is

July 02, 2021
First-line treatment of squamous non-small cell lung cancer! Kangfang Bio-PD-1 monoclonal antibody submitted a new indication for marketing application

On July 2, 2021, Kangfang Bio-Bio announced that the PD-1 monoclonal antibody drug Paimrizumab (R&D code: AK105, trad

July 01, 2021
"Drugs" become "luxuries", performance growth depends on price increases, is Pien Tze Huang still fragrant?

Recently, the national first-class confidential Chinese medicine Pill Zihuang's value has skyrocketed, with an ex-factory price of 590 yuan. E-commerce platforms ge

June 30, 2021
Reveal the list! The fifth batch of centralized procurement results announced

Just now, Shanghai Sunshine Pharmaceutical Purchasing Network announced the results of the

June 29, 2021
List of drugs that are expected to be negotiated for medical insurance in 2021! Qilu, Hengrui, Rongchang Biological...

Since 2016, the country has negotiated drug prices every year, and 5 rounds of medical insurance negotiations have been conducted. The first round of medical

June 28, 2021
[Yao Kajun] 37 new drugs were approved for clinical use, from CP Tianqing, Hengrui, Kelun...

Highlights: 1. 37 new drugs obtained implied approval for clin

June 26, 2021
The results of the fifth batch of national centralized purchasing are analyzed in 4 figures

The fifth batch of national procurement with volume (hereinafter referred to as "this national procurement") was carried out in Shanghai the d

June 19, 2021
Loss of 700 million a year! It only took 5 years from the establishment to the IPO. Why is Heyu Biotech?

The latest news on June 17th, Shanghai Heyu Biomedical Technology Co., Ltd. submitted a prospectus to the Hong Kong Stock Exchange on the even

June 18, 2021
There are nearly 50 dual antibodies under development in China, and Corning Jereh KN046 is expected to be listed in 2022; Kangfang Biology, Hengrui Medicine...

On June 7, Corning Jerry, the global leader in the development of PD-(L)1/CTLA-4 dual antibodies, announced PD-L1/CTLA-4 in the form of

June 17, 2021
About to break out! Contains a lot of unmet needs, the track that Hillhouse and Sequoia love super!

After the early collection of coronary stents and the upcoming blowout of orthopedic consumables, the market’s "favor and favor for de

June 16, 2021
Baike Biologics purchase day: there is no need to use the "nasal spray new crown vaccine", the shingles vaccine is the core growth point

A few days ago, at a press conference held by the Joint Prevention and Control Mechanism of the State Council, a reporter had just asked about

June 15, 2021
The gene therapy market broke out! The market size will exceed 30.54 billion U.S. dollars in 2025

Since 2015, the global gene therapy industry has accelerated its development and continued to make breakthroughs. Especially after 2017, with

June 11, 2021
First-line dual immunotherapy for pleural mesothelioma! Bristol-Myers Squibb's immune combination therapy approved in China

On June 10, according to the official website of the National Medical Products Administration (NMPA) of China, Bristol-Myers Squibb's immune c

Casa

Product

Whatsapp

Sobre nós

Inquérito

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

enviar